

## BIBLIOGRAPHY

- Acocella, G. and Conti, R. 1980. Interaction of rifampicin with other drugs. *Tubercel.* 61: 171-177.
- Avenoso, A., Facciola, G., Salemi, M. and Spina, E. 2000. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reverse-phase liquid chromatography with ultraviolet detection. *J. Chromatogr. B* 746: 173-181.
- Backman, J.T., Olkkola, K.T. and Neuvonen, P.J. 1996. Rifampicin drastically reduces plasma concentrations and effects of oral midazolam. *Clin. Pharmacol. Ther* 59: 7-13.
- Barbarash, R.A. 1985. Verapamil-rifampicin interaction. *Drug Intell. Clin Pharmacol.* 19: 559-560.
- Barditch-Crovo, P., Trapnell, C.B., Ette, E., Zacur, H.A., Coresh, J., Rocco, L.E., Hendrix, C.W. and Flexner, C. 1999. The effect of rifampicin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. *Clin Pharmacol Ther* 65: 428-438.
- Benet, L.Z., Izumi, T., Zhang, Y. 1999. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. *J. of Controlled release* 62(1-2): 25-31.
- Bersani, G., Bressa, G.M., Meco, G., Marini, S., Pozzi, F. 1990. Combined serotonin-5-HT<sub>2</sub> and dopamine-D<sub>2</sub> antagonism in schizophrenia : Clinical, extra pyramidal and neuroendocrine response in a preliminary study with risperidone (R64766). *Hum Psychopharmacol* 5: 225-231.
- Boman, G. Hanngren, A. and Malmborg, A.S. 1971. Drug interaction : decreased serum concentration of rifampicin when given with P.A.S. *Lancet* 17: 800.
- Boman, G. 1974. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid and isoniazid. *Eur.J. Clin. Pharmacol.* 7: 215-225.
- Borcherding, S.M., Bastian, T.L., Self, T.H., Abou-Shala, N., Leduc, B.W. and Lalonde, R.L. 1992. Two-and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism. *Antimicrob. Agents Chemother* 36: 1553-1558.

- Borin, M.T., Chamber, J.H., Carel, B.J., Gagnon, S. and Freimuth, W.W. 1997. Pharmacokinetic study of the interaction between rifampicin and delavirdine mesylate. *Clin. Pharmacol. Ther* 61: 544-553.
- Borison, R.L. *et al.* 1994. Pharmacokinetics of risperidone in chronic schizophrenia patients. *Psychopharmacology. Bull* 30(2): 599-605.
- Brown, K. *et al.* 1993. Overdose of risperidone. *Ann. Emerg* 28(12): 1908-1910.
- Burger, D.M., Meenhorst., P.L., Koks., C.H.W. and Beijnen, J.H. 1993. Pharmacokinetic interaction between rifampicin and zidavudine. *Antimicrob. Agents Chemother* 37: 1426-1431.
- Bussey, H.I., Merrit, G.L. and Hill, E.G. 1984. The influence of rifampin on quinidine and digoxin. *Arch. Intern. Med* 144 : 1021-1023.
- Chamber, H.F. and Jawetz, E. 1998. Antimycobacterial drugs. In B.G. Katzung (ed), *Basic and Clinical Pharmacology* (7<sup>th</sup> ed.), pp. 770-779. New Jersey: Prentice-Hall International Inc.
- Chenhsu, R.Y., Loong, C.C., Chou, M.H., Lin, M.F. and Yang, W.C. 2000. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. *The Annal of Pharmacotherapy* 34: 27-31.
- Choo, E.F., Leake, B., Wandel, C., *et al.* 2000. Pharmacological inhibition of P-glycoprotein transports enhances the distribution of HIV-1 protease inhibitors into brain and testes. *Drug Metab. Dispos* 28: 655-660.
- Chouinard, G. and Arnott, W. 1993. Clinical review of risperidone. *Can J Psychiatry* 38(3): 89-95.
- Cutler, N.R. 2001. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. *J. Clin. Psychiatry* 62: 10-13.
- Dilger, K., Hofmann, U. and Klotz, U. 2000. Enzyme induction in the elderly: effect of rifampicin on the pharmacokinetics and pharmacodynamics of propafenone. *Clin Pharmacol Ther* 67: 512-520.
- Doble, N., Shaw, R., Rowland-Hill, Lush M., Warnock, DW., Keal, EE. 1988. Pharmacokinetic study of interaction between rifampicin and ketoconazole. *J Antimicrob Chemother* 21: 633-635.

- Ebert, U., Thong, N.Q., Oertei, R. and Kirch W. 2000. Effect of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. *Eur J Clin Pharmacol* 56: 299-304.
- Fontaine, F., Sousa, G., Burcham, P.C., Duchene, P. and Rahmani, R. 2000. Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. *Life Science* 66(22): 2193-2212.
- Fromm, M.F., Busse, D., Kroemer, H.K. and Eichelbaum, M. 1996. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. *Hepatology* 24: 796-801.
- Gallicano, K.D., Sahai, J., Shukla, V.K., Seguin, I., Pakuts, A., Kwok, D., Foster, B.C. and Cameron, D. W. 1999. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV infected patients. *Br. J Clin Pharmacol* 48: 168-179.
- Garfield, J.W. and Giush, L.M. 1975. Rifampin-methadone interaction. *American review of Respiratory diseases* 3: 926.
- Gault, H., Langerich, L., Dawe, M. and Fine, A. 1984. Digoxin-rifampin interaction. *Clin Pharmacol Ther* 35: 752-754.
- Ged, C., Rouillon, JM. Pichard, L., Combalbert, J., Bressot, N. *et al.* 1989. The increase in Urinary excretion of 6(-hydroxycortisol) as a marker of human hepatic cytochrome P450 3A induction. *Br. J Clin Pharmacol* 28: 373-387.
- Gillum, J.G., Sesler, J.M., Bruzzese, V.L., Israel, D.S. and Poik, R.E. 1996. Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. *Antimicrob Agents Chemother* 40: 1866-1869.
- Gonzales, F.J., Kasper, CB. 1990. Phenobarbital induction of NADPH cytochrome c(P450) oxidoreductase messenger ribonucleic acid. *Biochemistry* 19: 1790-1796.
- Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.P., Richter, O.V., Zundler, J. and Kroemer, H.K. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. *J Clin Invest* 104(2): 147-153.
- Guengerich, F.R. 1988. Oxidation of 17 $\alpha$ -ethynylestradiol by human liver cytochrome P450. *Molecular Pharmacology* 33: 500-508.

- Gutierrez – Esteinou, R., *et al.* 1995. An open – lable extention study (RIS – USA – 9) to evaluate the long – term safety of risperidone in schizophrenic patients. *Janssen Rsearch Foundation Clinical Report*, November.
- Halpert, J.R. 1995. Structural basis of selective cytochrome P450 inhibition. *Annual Review of Pharmacology and Toxicology* 35: 29-53.
- Hamma, M.A., Bruce, M.a., Heahner-Daniels, B.D. and Hall, S.D. and Hall, S.D. 2001. The effect of rifampicin administration on the disposition of fexofenadine. *ClinPharmacol Ther* 69: 114-121.
- Hebert, M.F., Fisher, R.M., Marsh, C.L., Dressler, D. and Bekersky, I. 1999. Effects of rifampicin on tacrolimus pharmacokinetics in healthy volunteers. *J Clin Pharmacol.* 39: 91-96.
- Heimark, L.D., Gibaldi, M. Trager, W.F., O'Reilly, R.A. and Goulart, D.A. 1987. The mechanisms of warfarin-rifampicin drug interaction in human. *Clin Pharmacol Ther* 42: 388-394.
- Heykants, J. et al. 1994. The pharmacokinetics of risperidone in humans : a summary. *J Clin Psychiatry* 55: 13-17.
- Holdiness, M.R. 1984. Clinical pharmacokinetic infection between praziquantel and albendazole in Sudanese men. *Trop Med Parasitol* 88(5): 551-559.
- Huang, ML., Van, Peer A., Woestenborghs, R., de Coster, R., Heykants, J., Jansen, AA, et al. 1993. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in the healthy subjects. *Clin. Pharmacol. Ther* 54: 257-268.
- Hunt, CM., Westerkam, WR., Stave, GM. 1992. Effects of age and gender on the activity of human hepatic CYP 3A. *Biochem. Pharmacol* 44: 275-283.
- Hunter, J., Jepson, M.A., Tsuruo, T., Simmons, N.L. and Hirst, B.H. 1993. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. *J. Biol. Chem* 268: 14991-14997.
- Jaruratanasirikul, S. and Sriwiriyan, S. 1998. Effects of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. *Eur. J. Clin. Pharmacol* 54: 155-158.

- Janssen, PAJ., Niemegeers, CJE., *et al.* 1988. Pharmacology of risperidone, a new antipsychotic With serotonin-S<sub>2</sub> and dopamine-D<sub>2</sub> antagonistic properties. *J. Pharmacol Exp Ther* 244:685-693.
- Kim, R.B., Fromm, M.F., Wandel, C., *et al.* 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitor. *J. Clin Invest* 101:289-294.
- Kondo, T., Mihara, K., Suzuki, A., Ono, S. 2002. Genotyping analysis as a possible predictor of pharmacokinetic and clinical effects of antipsychotic drugs. *International Congress Series* 1244: 111-118.
- Kolars, JC., Schmiedlin-Ren, P., Scutz, JD., Fang, C., Watkins, PB. 1992. Identification of rifampicin-inducible P450 3A4 (CYP 3A4) in human small bowel enterocytes. *J. Clin Invest* 90: 1871-1878.
- Kyrklund, C., Backman, J.T., Kivisto, K.T., Neuvonen, M., Laitila, J. and Neuvonen, P.J. 2000. Rifampicin greatly reduces plasma simvastatin and simvastatin acid concentrations. *Clin Pharmacol Ther* 68: 592-597.
- Lee, K.H., Shin, J.G., Chong, W.S., Kim, S., Lee, J.S., Jang, I.J. and Shin, S.G. 1993. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. *Eur. J Clin Pharmacol* 45: 287-289.
- Lin, J.H. 2003. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. *Advanced Drug Delivery Reviews* 55: 53-81.
- Llerna, A., Berecz, R., Dorado, P. de la Rubia, A. 2004. QTc interval, CYP 2D6 and CYP 2C9 genotypes and risperidone plasma concentrations. *J. Psychopharmacol* 18: 189-193.
- Luchins, DJ., Klass, D., Hanrahan, P., Malan, R., Harris, J. 1998. Alteration in the recommended dosing schedule for risperidone. *Am. J. Psychiatry* 155: 365-366.
- Mandell, G.L. and Sandle, M.A. 1996. Antimicrobial agents : drug used in the chemotherapy of tuberculosis and leprosy. In L.S. Goodman and A.G. Gilman (eds.), *Pharmacological Basis of Therapeutics* (8<sup>th</sup> ed.), pp. 1146-1164. New York: McGraw-Hill.
- Marder, SR., Davis, JM., Chouinard, G. 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis : Combined results of the North American Trials. *J. Clin. Psychiatry* 58(12): 538-546.

- McDonnell, WM., Scheiman, JM., Traber, PG., 1992. Induction of cytochrome P450 1A (CYP 1A) by omeprazole in human alimentary tract. *Gastroenterology* 103: 1509-1516.
- Mcnicol, M.W., Campbell, I.A. and Jenkins, P.A. 1995. Clinical features and management. In R. Brewis, B. Corrin, D.M. Geddes and G.J. G.J. Gibson (eds.), *Respiratory Medicine* (2<sup>nd</sup> ed.), pp.805-832. London: Saunders Compang Ltd.
- Megens, AAHP., Awouters, FHL., Niemegeers, CJE. 1988. Differential effects of the new antipsychotic risperidone on large and small motor movements in rats : a comparison with haloperidol. *Psychopharmacology* 95: 493-496.
- Mesotten, F., *et al.* 1989. Therapeutic effect and safety of increasing dose of risperidone (R64766) in psychotic patients. *Psychopharmacology* 99: 445-449.
- Miguet, J.P., Mavier, P., Soussy, C.J. and Dhumeaux, D. 1997. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. *Gastroenterology* 72: 924-926.
- Moreno, S., Podzamczar, D., Blazquez, R., Iribabarren, J.A., Ferrer, E., Reparaz, J., Pena, J.M., Cabrero, E. and Usan, L. 2001. Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampicin. *AIDS*. 15(9):1185-1187.
- Muller-Spahn, F. 1992. Risperidone in the treatment of chronic schizophrenia patients : An international double-blind parallel-group study versus haloperidol. *Clin. Neuropharmacology* 15(1): 90A-91A.
- Nair, NP. 1998. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone group. *J. Clin. Pharmacology* 18(2):103-110.
- Niemegeers, F., Janssen, P., Awoutlas, F. *et al.* 1988. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S<sub>2</sub> and dopamine-D<sub>2</sub> antagonistics. *J. Pharmacology. Exp Ther* 244: 685-693.
- Niemi, M., Backman, JT., Neuvonen, M., Neuvonen, PJ., Kivisto, KT. 2000. Rifampicin decreases the plasma concentrations and effects of repaglinide. *Clin Pharmacol Ther* 68: 495-500.
- Nyberg, S., Farde, L., Eriksson, L., Halldin, C., Eriksson, B. 1993. 5-HT<sub>2</sub> and dopamine-D<sub>2</sub> receptor occupancy in the living human brain. *Psychopharmacology* 110: 265-272.

- O'Reilly, R.A. 1974. Interaction of sodium warfarin and rifampicin. *Ann. Intern. Med* 81: 337-340.
- Palkama, V.J., Ahonen, J., Neuvonen, P.J., *et al.* 1999. Effects of saquinavir on the pharmacokinetic and pharmacodynamics of midazolam. *Clin. Pharmacol. Ther* 55: 481-485.
- Peusken, J. 1995. Risperidone in the treatment of patients with chronic schizophrenia a multinational, multicentre, double – blind, parallel – group study versus haloperidol. *Br J Psychiatry* 166: 712-726.
- Polk, R.E., Crouch, M.A., Israel, D.S., Pastor, A., Sadler, B.M., Chittick, G.E., Symonds, W.T., Gouldin, W., Lou, Y. 1999. Pharmacokinetic interaction between ketoconazole and amprenavir after singledoses in healthy men. *Pharmacotherapy* 19(12): 1378-1384.
- Prober, C.G. 1985. Effect of rifampicin on chloramphenicol levels. *N. Engl. J. Med.* 312: 788-789.
- Remington, G. *et al.* 1998. American Psychiatric Association Practical Guideline for schizophrenia : risperidone equivalents. *Am. J. Psychiatry* 155(9): 1301-1302.
- Reynolds, J.E.F., Parfitt, K., Parson, A.V. and Sweetman, S.C. 1993. Martindale The Extra Pharmacopoeia (30<sup>th</sup> ed.), 2363 pp. London: The Pharmaceutical Press.
- Ribera, E., Pov. L., Fernandez-Sola, A., Campos, F., Lopez, R.M., Ocana, I., Rviz, I. and Pahissa, A. 2001. Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients. *Antimicrob. Agents Chemother* 45(11): 3238-3241.
- Riditid, W., Wongnawa, M., Mahatthanatrakul, W., Chaipol, P., Sunbhanich, M. 2000. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. *J Pharm Pharmacol* 52: 1265-1269.
- Riditid, W., Wongnawa, M., Mahatthanatrakul, W., Jarurat, P. 2002. The effect of rifampicin on pharmacokinetics of single and multiple oral doses of praziquantel in healthy volunteers. *Clin. Pharmacol. Ther* 72(5): 505-513.
- Robson, R.A., Miners, J.O., Wing, L.M.H., Birkett, D.J. 1984. Theophylline-rifampicin interaction:non-selective induction of theophylline metabolic pathways. *Br. J. Clin. Pharmacol* 18: 445-448.

- Scordo, MG., Spina, E., Facciola, G., Avenoso, A., Johansson, I., Dahl, ML. 1999. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxy risperidone. *Psychopharmacology (Berl)* 147: 300-305.
- Siegler, D.I., Bryant, M., Burley, D.M., Citron, K.M. and Standen, S.M. 1974. Effect of meals on rifampicin absorption. *Lancet* 27: 197-198.
- Siverman, J.A. 2000. P-glycoprotein. In R. H. Levy, *Metabolic drug interactions*. pp. 135-144. Philadelphia: A wolters Kluwer.
- Strayhorn, V.A., Bacicwicz, A.M., Self, T.H. 1997. Update on rifampicin drug interactions III. *Arch. Intern. Med* 157: 2453-2458.
- Syvalathi, E.K.G., Pihlajamaki, K.K. and Lisalo, E.J. 1974. Rifampicin and drug metabolism. *Lancet* 2: 232-233.
- Syvalathi, E.K.G., Pihlajamaki, K.K. and Lisalo, E.J. 1975. Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide and on the half-life of tobutamide. *Intern. J. Clin. Pharmacol. Toxicol. Ther* 13: 83-89.
- Tracy, J.W. and Webster, L.T. 2001. Drugs used in the chemotherapy of helminthiasis. In Hardman, J.G. and Limbird L.E., *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (10<sup>th</sup> ed.) pp. 1121-1140. New york: Mcgraw-Hill.
- Venkatakrishnan, K., Von Moltke, L.L., Greenblatt, D.J. 2000. Effects of the antifungal agents on oxidative drug metabolism. *Pharmacokinetic* 38(2): 111-180.
- Umbricht, D. and Kane, JM. 1995. Risperidone: Efficacy and safety. *Schizophr Bull* 22: 593-606.
- Venkatesan, K. 1992. Pharmacokinetic drug interactions with rifampicin. *Clin Pharmacokinet* 22: 47-65.
- Villikka, K., Kivisto, KT., Backman, JT., Olkkola, KT., Neuvonen, PJ. 1996. Triazolam is ineffective in patients taking rifampin. *Clin Pharmacol Ther* 61: 8-14.
- Villikka, K., Kivisto, K.T. and Neuvonen, P.J. 1999. The effect of rifampicin on the oral and intravenous ondansetron. *Clin Pharmacol Ther* 65: 377-381.
- William, A. and Petri, Jr. 2001. Antimicro agents. In Hardman, J.G. and Limbird L.E. *Goodman A.G. and Gilman L.S. Pharmacological Basis of Therapeutics* (10<sup>th</sup> ed.), pp. 1273-1294. New York: McGraw-Hill.



Zhang, Y. and Benet, L.Z. 2001. The gut as a barrier to drug absorption combined role of cytochrome P450 3A and P-glycoprotein. *Clin Pharmacol* 40(3): 159-168.